Vaxcyte, Inc. (PCVX)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-05) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-06) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-24) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-04) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-06) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-07) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-25) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-05) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-06) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-08) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-27) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-06) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Document and Entity Information | ||
| Audit Information | — |
|
| Statements | ||
| Condensed Balance Sheets (unaudited) | — |
|
| Consolidated Balance Sheets | ||
| Condensed Balance Sheets (P) (unaudited) | — |
|
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Statements of Operations | ||
| Consolidated Statements of Comprehensive Loss | ||
| Statements of Operations (P) | — |
|
| Consolidated Statements of Stockholders Equity | ||
| Statements of Comprehensive Loss | ||
| Consolidated Statements of Stockholders Equity (P) | ||
| Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (P) | ||
| Statements of Cash Flows (unaudited) | ||
| Notes | ||
| Balance Sheet Details | ||
| Basis of Presentation and Summary of Significant Accounting Policies | ||
| Commercial Manufacturing and Supply Agreement | ||
| Commitments and Contingencies | ||
| Common Stock | — |
|
| Company Organization and Nature of Business | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Equity Incentive Plans | ||
| Fair Value Measurements and Fair Value of Financial Instruments | ||
| Funding Arrangement | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | ||
| Net Loss Per Share | ||
| Pay Vs Performance Disclosure | ||
| Pre-funded Warrants | ||
| Related Party Transactions | — |
|
| Retirement Plan | ||
| Segment Reporting | ||
| Stockholders' Equity | ||
| Subsequent Events | ||